Home › Mieloma multiplo › Washington
Studi clinici su Mieloma multiplo nello stato di Washington
30 studi su Mieloma multiplo cercano partecipanti presso sedi nello stato di Washington.
Città nello stato di Washington
Testo ufficiale dello studio (inglese)
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 103, Tacoma
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07582432A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Puyallup
- Research Site, Seattle
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Washington, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT04973605A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NorthWest Medical Specialties, PLLC, Tacoma
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05552222A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- University of Washington, Seattle
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06500884A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- NorthWest Medical Specialties, PLLC, Tacoma
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07518186Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Northwest Medical Specialties, PLLC, Tacoma
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07609940A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Optum Care Washington, Everett
- American Oncology Network Vista Oncology Division / Physician partner associate, Olympia
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT07477587TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Northwest Medical Specialties, Bonney Lake
- Northwest Medical Specialties, Federal Way
- Northwest Medical Specialties, Gig Harbor
- e altri 4
In reclutamentoFase 2
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07181941Collection of Tissue Samples for Cancer Research
- Fred Hutchinson, Seattle
In reclutamentoStudio osservazionale
2 Months · Tutti i sessi · Aggiornato il 16 set 2026 · NCT00900198A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Northwest Medical Specialties Tacoma /ID# 272506, Tacoma
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06953960Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06297226Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Northwest Medical Specialties, Tacoma
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Edmonds
- Research Site, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Puyallup
- Research Site, Seattle
- Research Site, Seattle
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT07764978Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Fred Hutch Cancer Center, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 lug 2026 · NCT02343042A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fred Hutchinson Cancer Center. /ID# 267940, Seattle
- Northwest Medical Specialties Tacoma /ID# 267117, Tacoma
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 lug 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- VA Puget Sound Health Care System, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 lug 2026 · NCT05137054Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Harrison Medical Center, Bremerton
- e altri 15
In reclutamentoFase 3
Tutte le età · Tutti i sessi · Aggiornato il 10 giu 2026 · NCT05561387Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 mag 2026 · NCT06433947Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Swedish Medical Center - Seattle /ID# 268052, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 mag 2026 · NCT06896916A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Puyallup
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT06679101Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Swedish Cancer Institute, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 apr 2026 · NCT03761108A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Swedish Medical Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 mar 2026 · NCT06153251PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
- University of Washington, Seattle
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 apr 2025 · NCT05956457Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
- University of Washington, Seattle
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 dic 2024 · NCT05053607Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
- All4Cure, Seattle
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 mag 2024 · NCT06149910Fonte: ClinicalTrials.gov, dati recuperati il 2 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.